RxSight (NASDAQ:RXST) Announces Quarterly Earnings Results, Misses Expectations By $0.07 EPS

RxSight (NASDAQ:RXST) posted its quarterly earnings data on Wednesday. The company reported ($0.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.07), FiscalAI reports. RxSight had a negative return on equity of 14.05% and a negative net margin of 28.96%.The firm had revenue of $30.89 million during the quarter, compared to analyst estimates of $29.75 million. During the same quarter in the previous year, the firm posted ($0.03) earnings per share. The company’s quarterly revenue was down 18.5% on a year-over-year basis.

Here are the key takeaways from RxSight’s conference call:

• Management says LAL utilization has stabilized for a third consecutive quarter and their customer re‑engagement programs are showing early, measurable improvements in practices that receive targeted clinical reviews and workflow support.
• Q1 sales were $30.9 million (down 18% YoY), GAAP net loss was $15.9 million, and only 20 LDDs were sold in the quarter, highlighting near‑term revenue and profitability pressure.
• The company reiterated full‑year 2026 revenue guidance of $120M–$135M and gross margin guidance of 70%–72%, but expects a margin step‑down as higher‑cost 2025 inventory is absorbed and plans OpEx at the high end of the prior $150M–$160M range to fund commercial expansion.
• International expansion is progressing (recent approval in New Zealand and activity across Europe, Korea and Australia); management expects modest 2026 contribution with the international business becoming a more meaningful growth driver in 2027 and beyond.
• RxSight plans product enhancements (PMA supplements in process) aimed at simplifying LAL implementation, reducing required LDD treatments, and extending correction range, which management says should lower adoption friction and support longer‑term growth.

RxSight Trading Down 6.6%

Shares of RxSight stock traded down $0.48 on Wednesday, hitting $6.78. 1,396,729 shares of the company were exchanged, compared to its average volume of 621,828. The company has a 50-day moving average price of $7.21 and a 200 day moving average price of $8.96. RxSight has a 1-year low of $5.90 and a 1-year high of $16.74.

Analyst Ratings Changes

Several research firms recently issued reports on RXST. Stifel Nicolaus lowered their price objective on RxSight from $10.00 to $9.00 and set a “hold” rating on the stock in a report on Monday, March 9th. Wolfe Research upgraded RxSight to an “outperform” rating in a report on Friday, January 30th. Needham & Company LLC restated a “buy” rating and set a $13.00 target price on shares of RxSight in a report on Thursday, February 26th. William Blair started coverage on RxSight in a report on Friday, January 30th. They set a “market perform” rating on the stock. Finally, UBS Group boosted their target price on RxSight from $8.00 to $9.00 and gave the stock a “neutral” rating in a report on Thursday, February 26th. Two research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and three have given a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Reduce” and an average target price of $9.78.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in RXST. Raymond James Financial Inc. acquired a new position in RxSight in the second quarter valued at approximately $28,000. Larson Financial Group LLC lifted its holdings in RxSight by 110.5% in the third quarter. Larson Financial Group LLC now owns 3,979 shares of the company’s stock valued at $36,000 after acquiring an additional 2,089 shares during the last quarter. Caitong International Asset Management Co. Ltd lifted its holdings in RxSight by 440.7% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 3,758 shares of the company’s stock valued at $39,000 after acquiring an additional 3,063 shares during the last quarter. Tower Research Capital LLC TRC lifted its holdings in RxSight by 156.2% in the second quarter. Tower Research Capital LLC TRC now owns 5,574 shares of the company’s stock valued at $72,000 after acquiring an additional 3,398 shares during the last quarter. Finally, Aquatic Capital Management LLC lifted its holdings in RxSight by 200.3% in the third quarter. Aquatic Capital Management LLC now owns 11,043 shares of the company’s stock valued at $99,000 after acquiring an additional 7,366 shares during the last quarter. 78.78% of the stock is currently owned by institutional investors and hedge funds.

RxSight Company Profile

RxSight, Inc is a medical technology company focused on the development and commercialization of advanced intraocular lens (IOL) systems for patients undergoing cataract surgery and lens replacement procedures. The company’s flagship product, the Light Adjustable Lens (LAL), is designed to provide customized vision correction by allowing non‐invasive post‐operative adjustments. Using ultraviolet light, surgeons can fine‐tune the lens power after implantation to achieve optimal visual outcomes, reducing reliance on glasses or contact lenses and enhancing patient satisfaction.

Founded in 2011 and headquartered in Aliso Viejo, California, RxSight has pursued regulatory clearances and market access across multiple regions.